US-based Exact Sciences Corporation intends to raise $245m in gross proceeds through a public offering of its common stock shares.
The offering includes seven million shares priced at $35 a share, while underwriters have an option to purchase up to an additional 1.05 million shares.
Go deeper with GlobalData
The proceeds will be used to mainly expand the commercialisation activities of Cologuard, a non-invasive, colon cancer at-home test. Part of the proceeds will also be used for product development and for general corporate and working capital purposes.
US-based pharmaceutical company Egalet Corporation and Ascend Therapeutics US have signed a two-year co-promotion agreement for SPRIX (ketorolac tromethamine), a nasal spray used for management of moderate-to-moderately severe pain.
Ascend Therapeutics’ team will help co-promote the product as part of the agreement, starting from this year's third quarter.
Israeli-based Tisbury Pharmaceuticals has announced its completion of the first round of venture financing to raise $32m from OrbiMed Advisors, Clarus Healthcap, and Pontifax.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe proceeds are intended to be used to conduct human trials and develop other glaucoma drugs.
